DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer

(2:8)

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancer

(1:32)

DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases

(1:33)

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

(56)

DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasis

(45)

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers

(2:31)

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

(1:8)

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01

(3:36)

Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer

(1:34)

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer

(1:8)

Highlights from ESMO: DESTINY-Breast03

(48)

SABCS 2022: DESTINY-Breast02 + DESTINY-Breast03

(2:16)

DESTINY-Breast15: anticipating the impact of HER2-low status

(40)

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo...

(7:12)

DESTINY-Breast01: a new “destiny” for HER2positive mBC patients?

(1:33)

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

(4:7)

Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04

(45)

Detailed safety analysis from the DESTINY-Breast04 trial

(6:33)

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

(1:8)